We analyzed the role of intravenous digital subtraction angiography (DSA), with neck and intracranial views as a definitive pretherapy study, in patients who had symptomatic cerebral ischemia. Eighty-six patients, 25 of whom had subsequent carotid thromboendarterectomy, were examined. An adequate pretherapy intravenous DSA study allowed us to define each carotid bifurcation as either normal, having insignificant stenosis, or having significant stenosis, and the examination excluded significant tandem stenosis in the intracranial internal carotid arteries. Adequate pretherapy intravenous DSA studies were obtained in 73% of patients, including 50% of those in the presurgical group. Selective carotid arteriography was not required in these patients. Inadequate presurgical studies were predominantly due to plaque misregistration, inadequate projection, and superimposition that obscured the proximal internal carotid arteries. Selective carotid arteriography was performed in these patients prior to surgery. Inadequate studies prior to initiation of medical therapy were predominantly due to soft tissue misregistration artifact, and superimposition. Intravenous DSA is a valuable screening test and can be used to guide therapy in the majority of patients who have symptomatic cerebral ischemia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1148/radiology.151.3.6371889 | DOI Listing |
Hematology
December 2025
Cellular Therapy & Transplantation Program, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada.
Umbilical cord blood (UCB) represents a valuable graft source in the absence of a human leukocyte antigen (HLA)-matched donor for hematopoietic cell transplantation (HCT). Donor-specific anti-HLA antibodies (DSAs), targeting grafts with mismatched HLA antigens, pose a significant obstacle by increasing the risk of primary graft failure, delayed engraftment, and decreased survival. Existing literature on HLA desensitization has primarily focused on haploidentical transplants, and there is a lack of experience regarding the optimal strategy in UCB transplantation.
View Article and Find Full Text PDFClin Pharmacokinet
December 2024
Clinical Pharmacology, AbbVie Inc., Dept R4PK, Bldg AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA.
Background And Objective: The objective of this study was to characterize the effects of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates in patients with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC) using a cocktail approach.
Methods: Patients with CD or UC (n = 20) received single doses of probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) before and after intravenous infusions of risankizumab 1800 mg once every 4 weeks for four doses. Serial blood samples were collected for determination of concentrations of the CYP probe drugs and metabolites with and without risankizumab.
AJNR Am J Neuroradiol
November 2024
From the Department of Radiology and Radiological Sciences (D.A.L., A.B.B., H.S., R.W., J.M., V.Y.), and Department of Neurology (A.E.H.), Johns Hopkins University, Baltimore, MD, USA; Department of Neuroradiology (D.A.L., S.A., M.K., A.T.R.), and Department of Biostatistics (S.W.), West Virginia University, Morgantown, WV, USA; Cooper Medical School of Rowan University (M.K.), Camden, NJ, USA; Department of Neurology (J.J.H., G.W.A.), Stanford University, Stanford, CA, USA; Department of Radiology (A.A.D.), Harvard Medical School, Boston, MA, USA; Department of Radiology, Neuroendovascular Division (T.D.F.), University Medical Center Münster, Germany; Department of Neuroradiology (M.W.), MD Anderson Medical Center, Houston, TX, USA; Department of Radiology (K.N.), University of California San Francisco, CA, USA.
: Pretreatment CTA-based Cortical Vein Opacification Score (COVES) has been shown to predict good functional outcomes at 90 days in patients with acute ischemic stroke secondary to large vessel occlusion (AIS-LVO). This is thought to be related to its ability to measure collateral status (CS). However, its association with the reference standard test, the DSA-based American Society of Interventional and Therapeutic Neuroradiology (ASITN) collateral score, has yet to be established.
View Article and Find Full Text PDFJ Clin Apher
December 2024
Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, USA.
Antibody-mediated rejection (AMR) in lung transplantation has been associated with poor long-term clinical course and is a risk factor for chronic lung allograft dysfunction and graft loss. Appropriate management of AMR is necessary to improve graft survival in lung transplant recipients. There is currently no standardized approach to the treatment of lung AMR, and practices vary by institution.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!